Review
Aug 2026
Possibilities of antihypertensive therapy with a drug based on small interfering ribonucleic acid
The potential for treating hypertension with an injectable drug based on small interfering ribonucleic acid called zilebesiran is being actively studied, and a single subcutaneous administration of zilebesiran resulted in a significant reduction in blood pressure, with the effect lasting for up to 6 months.
P. Filiniuk, A. Rumyantsev, I. Pchelin et al.
· Vrach · 0 citations